Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

Jae Cheol Jo, Misung Kim, Yunsuk Choi, Hyun Jung Kim, Ji Eun Kim, Seoung Wan Chae, Hawk Kim, Hee Jeong Cha

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are new therapeutic targets in cancer immunotherapy. The aim of this study was to investigate the clinicopathological characteristics of PD-1 and PD-L1 expression in extranodal natural killer/T‑cell lymphoma, nasal type (ENKTL). We performed PD-1 and PD-L1 immunostaining in 79 ENKTL biopsy samples and retrospectively analyzed medical records of all 79 patients from four tertiary referral hospitals. The expression of PD-1 and PD-L1 by tumor cells and/or infiltrating immune cells was evaluated. The expression rates of PD-L1 in tumor cells and infiltrating immune cells were 79.7 and 78.5 %, respectively, whereas PD-1 in tumor cells and infiltrating immune cells were 1.3 and 11.4 %. The PD-L1 positivity in tumor cells and infiltrating immune cells was significantly associated with low international prognostic index (IPI) (P = 0.044 and 0.037, respectively). Patients with normal range of serum lactate dehydrogenase demonstrated a significantly higher PD-L1 positivity in tumor cells (P = 0.020). PD-L1-positive patients had a trend toward better overall survival compared with that in patients with PD-L1-negative in tumor cells and infiltrating immune cells (P = 0.498 and 0.435, respectively). The expression rate of PD-L1 was up to 79.7 % in ENKTL, while PD-1 expression rate was very low. This is the first report describing the clinicopathological features and survival outcome according to expression of PD-1 and PD-L1 in ENKTL.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalAnnals of Hematology
Volume96
Issue number1
DOIs
StatePublished - 1 Jan 2017

Fingerprint

CD274 Antigen
Extranodal NK-T-Cell Lymphoma
Cell Death
Ligands
Nose
Lymphoma
Neoplasms
Survival

Keywords

  • Immunohistochemistry
  • NK/T-cell lymphoma
  • PD-1
  • PD-L1

Cite this

Jo, Jae Cheol ; Kim, Misung ; Choi, Yunsuk ; Kim, Hyun Jung ; Kim, Ji Eun ; Chae, Seoung Wan ; Kim, Hawk ; Cha, Hee Jeong. / Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. In: Annals of Hematology. 2017 ; Vol. 96, No. 1. pp. 25-31.
@article{eb89f38779474df5bb8503ea2648efcf,
title = "Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type",
abstract = "Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are new therapeutic targets in cancer immunotherapy. The aim of this study was to investigate the clinicopathological characteristics of PD-1 and PD-L1 expression in extranodal natural killer/T‑cell lymphoma, nasal type (ENKTL). We performed PD-1 and PD-L1 immunostaining in 79 ENKTL biopsy samples and retrospectively analyzed medical records of all 79 patients from four tertiary referral hospitals. The expression of PD-1 and PD-L1 by tumor cells and/or infiltrating immune cells was evaluated. The expression rates of PD-L1 in tumor cells and infiltrating immune cells were 79.7 and 78.5 {\%}, respectively, whereas PD-1 in tumor cells and infiltrating immune cells were 1.3 and 11.4 {\%}. The PD-L1 positivity in tumor cells and infiltrating immune cells was significantly associated with low international prognostic index (IPI) (P = 0.044 and 0.037, respectively). Patients with normal range of serum lactate dehydrogenase demonstrated a significantly higher PD-L1 positivity in tumor cells (P = 0.020). PD-L1-positive patients had a trend toward better overall survival compared with that in patients with PD-L1-negative in tumor cells and infiltrating immune cells (P = 0.498 and 0.435, respectively). The expression rate of PD-L1 was up to 79.7 {\%} in ENKTL, while PD-1 expression rate was very low. This is the first report describing the clinicopathological features and survival outcome according to expression of PD-1 and PD-L1 in ENKTL.",
keywords = "Immunohistochemistry, NK/T-cell lymphoma, PD-1, PD-L1",
author = "Jo, {Jae Cheol} and Misung Kim and Yunsuk Choi and Kim, {Hyun Jung} and Kim, {Ji Eun} and Chae, {Seoung Wan} and Hawk Kim and Cha, {Hee Jeong}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00277-016-2818-4",
language = "English",
volume = "96",
pages = "25--31",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. / Jo, Jae Cheol; Kim, Misung; Choi, Yunsuk; Kim, Hyun Jung; Kim, Ji Eun; Chae, Seoung Wan; Kim, Hawk; Cha, Hee Jeong.

In: Annals of Hematology, Vol. 96, No. 1, 01.01.2017, p. 25-31.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

AU - Jo, Jae Cheol

AU - Kim, Misung

AU - Choi, Yunsuk

AU - Kim, Hyun Jung

AU - Kim, Ji Eun

AU - Chae, Seoung Wan

AU - Kim, Hawk

AU - Cha, Hee Jeong

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are new therapeutic targets in cancer immunotherapy. The aim of this study was to investigate the clinicopathological characteristics of PD-1 and PD-L1 expression in extranodal natural killer/T‑cell lymphoma, nasal type (ENKTL). We performed PD-1 and PD-L1 immunostaining in 79 ENKTL biopsy samples and retrospectively analyzed medical records of all 79 patients from four tertiary referral hospitals. The expression of PD-1 and PD-L1 by tumor cells and/or infiltrating immune cells was evaluated. The expression rates of PD-L1 in tumor cells and infiltrating immune cells were 79.7 and 78.5 %, respectively, whereas PD-1 in tumor cells and infiltrating immune cells were 1.3 and 11.4 %. The PD-L1 positivity in tumor cells and infiltrating immune cells was significantly associated with low international prognostic index (IPI) (P = 0.044 and 0.037, respectively). Patients with normal range of serum lactate dehydrogenase demonstrated a significantly higher PD-L1 positivity in tumor cells (P = 0.020). PD-L1-positive patients had a trend toward better overall survival compared with that in patients with PD-L1-negative in tumor cells and infiltrating immune cells (P = 0.498 and 0.435, respectively). The expression rate of PD-L1 was up to 79.7 % in ENKTL, while PD-1 expression rate was very low. This is the first report describing the clinicopathological features and survival outcome according to expression of PD-1 and PD-L1 in ENKTL.

AB - Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are new therapeutic targets in cancer immunotherapy. The aim of this study was to investigate the clinicopathological characteristics of PD-1 and PD-L1 expression in extranodal natural killer/T‑cell lymphoma, nasal type (ENKTL). We performed PD-1 and PD-L1 immunostaining in 79 ENKTL biopsy samples and retrospectively analyzed medical records of all 79 patients from four tertiary referral hospitals. The expression of PD-1 and PD-L1 by tumor cells and/or infiltrating immune cells was evaluated. The expression rates of PD-L1 in tumor cells and infiltrating immune cells were 79.7 and 78.5 %, respectively, whereas PD-1 in tumor cells and infiltrating immune cells were 1.3 and 11.4 %. The PD-L1 positivity in tumor cells and infiltrating immune cells was significantly associated with low international prognostic index (IPI) (P = 0.044 and 0.037, respectively). Patients with normal range of serum lactate dehydrogenase demonstrated a significantly higher PD-L1 positivity in tumor cells (P = 0.020). PD-L1-positive patients had a trend toward better overall survival compared with that in patients with PD-L1-negative in tumor cells and infiltrating immune cells (P = 0.498 and 0.435, respectively). The expression rate of PD-L1 was up to 79.7 % in ENKTL, while PD-1 expression rate was very low. This is the first report describing the clinicopathological features and survival outcome according to expression of PD-1 and PD-L1 in ENKTL.

KW - Immunohistochemistry

KW - NK/T-cell lymphoma

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=84989967036&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2818-4

DO - 10.1007/s00277-016-2818-4

M3 - Article

C2 - 27696202

AN - SCOPUS:84989967036

VL - 96

SP - 25

EP - 31

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -